About this Research Topic
Statins have been considered as the first-line treatment for atherosclerotic cardiovascular disease (ASCVD) for more than twenty years. Strong pieces of evidence suggested that statins could reduce the risk of ASCVD effectively. On the other hand, the increased risk of new-onset diabetes mellitus (NODM) has aroused the attention of clinicians and patients in recent years. The risk was higher in patients receiving high-intensity statin therapy and those with metabolic syndrome or prediabetes. Up to now, many animal and clinical studies have been reported to explore the pathophysiology mechanism. But the exact mechanism of these side effects seems to be multifactorial and remains unclear. Some studies suggested that reducing the activity of HMG-CoA reductase might impair the secretion function of pancreatic β-cells and increase insulin resistance in peripheral tissues. Even so, the cardiovascular benefits of statin therapy far outweigh the risk of adverse effects. We need accurately assess the incidence of NODM during statins treatment in a reasonable perspective, rather than exaggerating the perception of side effects among patients, the general public and some healthcare providers.
This Research Topic aims to explore the underlying mechanisms between statins and NODM. We also hope to gain insight from experts across fields, including cardiovascular medicine, endocrinology, epidemiology, pharmacology, biochemical and chemical genetics, and pathophysiology, in order to synthesize a multi-disciplinary review, relevant to patient care and informing future research and clinical practice.
The current Research Topic encourages Original Research, Reviews, or other accepted article types relating, but not limited to:
• Epidemiology and risk factors on NODM during statin treatment;
• Mechanisms of statins inducing NODM;
• Pharmacokinetics of statins, including muti-omics advances;
• Strategies for preventing NODM during lipid-lowering treatment;
• Class effect of different statins inducing NODM;
• Effects of complication in diabetes mellitus with or without long-term statins.
This Research Topic aims to explore the underlying mechanisms between statins and NODM. We also hope to gain insight from experts across fields, including cardiovascular medicine, endocrinology, epidemiology, pharmacology, biochemical and chemical genetics, and pathophysiology, in order to synthesize a multi-disciplinary review, relevant to patient care and informing future research and clinical practice.
The current Research Topic encourages Original Research, Reviews, or other accepted article types relating, but not limited to:
• Epidemiology and risk factors on NODM during statin treatment;
• Mechanisms of statins inducing NODM;
• Pharmacokinetics of statins, including muti-omics advances;
• Strategies for preventing NODM during lipid-lowering treatment;
• Class effect of different statins inducing NODM;
• Effects of complication in diabetes mellitus with or without long-term statins.
Keywords: Statin, New-Onset Diabetes Mellitus (NODM), β-cell, Insulin Resistance, Insulin Signal Pathway, Genetic, Risk Factor, Complication, Atherosclerotic Cardiovascular Disease (ASCVD)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
